Company Overview
Ginkgo Bioworks Holdings, Inc. operates as a developer of a cell engineering platform, providing research and development solutions alongside specialized cell engineering tools through its Cell Engineering and Biosecurity segments within the United States. This entity functions within the broader Healthcare sector and specifically the Biotechnology industry, positioning itself as a technology-focused biomanufacturing company rather than a traditional product manufacturer. The company's current market capitalization stands at $455.76M, reflecting a valuation that is significantly smaller than large-cap peers, while its trailing twelve-month revenue of $170.16M and workforce of 485 employees indicate a mid-sized operational scale. These financial figures suggest that Ginkgo Bioworks is a capital-intensive research organization where the market cap represents a premium based on intellectual property and platform potential, yet the revenue level highlights the ongoing challenge of scaling commercial operations to match the growth expectations inherent in its biotechnology industry classification.
Financial Health
The company reported revenue of $170.16M over the trailing twelve months, but this top-line figure masks a substantial operational deficit, as net income for the same period was -$312,763,008, indicating that costs far exceed revenue generation. The EBITDA stands at -$267,822,000, which, when combined with the net loss, reveals a cost structure characterized by high fixed costs in research and development that are not fully covered by current sales. Free cash flow is reported at -$72,883,000, signaling that the company is burning cash to fund its operations and strategic initiatives, thereby limiting its financial flexibility and reliance on external capital sources. Margin analysis shows a gross margin of 72.4%, suggesting efficient production or service delivery relative to direct costs, yet this is offset by an operating margin of -209.7% and a profit margin of -183.8%, both of which indicate severe overhead burdens or significant non-operating expenses impacting profitability. On the balance sheet, total cash holdings of $422.62M are slightly lower than total debt of $439.88M, resulting in a debt-to-equity ratio of 86.49, which characterizes the company as highly leveraged rather than conservative. Despite this leverage, the current ratio of 4.92 suggests that the company maintains strong short-term liquidity, as its current assets are nearly five times its current liabilities. Furthermore, the return on equity is -51.1% and the return on assets is -15.4%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and creditors.
Valuation Assessment
Valuation multiples for Ginkgo Bioworks present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive net income, while the forward P/E is negative at -2.03, implying that the market prices in a recovery of earnings rather than current profitability. The price-to-book ratio is 0.84, indicating that the stock trades below its book value, which often suggests the market is discounting the company's assets or future potential due to its current financial losses. Alternative valuation metrics include a price-to-sales ratio of 2.68 and an EV/EBITDA of -1.66, both of which suggest the market is assigning value based on revenue generation and enterprise value relative to earnings before interest, taxes, depreciation, and amortization, despite the negative earnings trajectory. In terms of price action, the 52-week high is $17.58 and the 52-week low is $5.00, meaning the current price sits within a wide trading range that reflects high volatility and uncertainty regarding the company's future valuation multiple. The beta is 1.59, which indicates that the stock's price volatility is significantly higher than the broader market, moving with greater intensity than the S&P 500 and amplifying both potential gains and potential losses for holders.
Growth & Income
The company's revenue growth year-over-year is -23.8%, while earnings growth is N/A due to the absence of positive earnings, a combination that implies the business is contracting in terms of top-line sales without the cushion of profitability to absorb the decline. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all available capital back into its operations, research, and platform development rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology firms in the development stage but necessitates continuous access to capital markets to fund the negative cash flow and operational losses. Overall, the growth and income profile for Ginkgo Bioworks Holdings is defined by a contraction in revenue, a lack of dividend income, and a heavy reliance on equity financing to sustain operations in a highly competitive and capital-intensive sector.